Clinical trial
A Randomized, Controlled, Open-Label, Multi-center Study of Becotatug Vedotin (EGFR-ADC) Combined With Chemo and Immunotherapy vs. Chemo and Immunotherapy as First-Line Treatment in Advanced/Metastatic EGFR-Mutated Biliary Tract Cancer
NCT07598318 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Open-Label, Multi-center Study of Becotatug Vedotin (EGFR-ADC) Combined With Chemo and Immunotherapy vs. Chemo and Immunotherapy as First-Line Treatment in Advanced/Metastatic EGFR-Mutated Biliary Tract Cancer
- Lead sponsor
- Sir Run Run Shaw Hospital
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- May 20, 2026
- Completion date
- December 31, 2028
- Enrollment
- 164 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.